Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Pharma
J&J, Legend's Carvykti shows 45% survival benefit in myeloma
Johnson & Johnson and Legend Biotech’s Carvykti has once again demonstrated a major benefit—this time in prolonging patients’ lives.
Angus Liu
Sep 30, 2024 9:50am
J&J counters Sanofi's Sarclisa nod with Darzalex data drop
Sep 27, 2024 3:59pm
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
Sep 25, 2024 10:52am
Sanofi moves on J&J's Darzalex in first-line myeloma with FDA nod
Sep 20, 2024 4:06pm
Legend CEO talks BIOSECURE Act, M&A rumor and Carvykti growth
Aug 9, 2024 10:30am
With FDA nod, J&J touts new 'foundational' multiple myeloma combo
Jul 31, 2024 10:39am
